Exploiting Cancer Synthetic Lethality in Cancer-Lessons Learnt from PARP Inhibitors.

Pettitt, Stephen J; Ryan, Colm J; Lord, Christopher J

Pettitt, Stephen J; Ryan, Colm J; Lord, Christopher J.

Afiliação

Pettitt SJ; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK.
Ryan CJ; School of Computer Science and Systems Biology Ireland, University College Dublin, Dublin, Ireland.
Lord CJ; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK. Chris.Lord@icr.ac.uk.

Cancer Treat Res ; 186: 13-23, 2023.

Article em En | MEDLINE | ID: mdl-37978128

Assuntos

Antineoplásicos; Neoplasias; Humanos; Inibidores de Poli(ADP-Ribose) Polimerases/farmacologia; Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico; Mutações Sintéticas Letais; Neoplasias/tratamento farmacológico; Antineoplásicos/uso terapêutico

Palavras-chave

Cancer; Drug resistance; PARP inhibitors; Synthetic lethality

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google